- Lexaria, a global specialist in drug delivery platforms, just announced the final results from its recently completed human Pilot Study #1 on the effectiveness of its patented DehydraTECH(TM) technology on the oral delivery of GLP-1 drug, semaglutide
- The results showed improved delivery of semaglutide to the bloodstream, with the drug showing approximately 44% higher levels than the control 24 hours after ingestion of a single dose
- DehydraTECH GLP-1 processed semaglutide also proved to be better tolerated than the control, with the latter resulting in some cases of moderate nausea and diarrhea
- This milestone brings Lexaria closer to tapping into the diabetes and weight loss treatment market and sets the company up for what is expected to be its best year
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the final results from its recently completed human Pilot Study #1 that sought to evaluate the effectiveness of its patented DehydraTECH(TM) technology on the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug semaglutide, available commercially in the branded product Rybelsus(R). The drug is approved by the Food and Drug Administration (“FDA”), given its role in promoting insulin production in the body, which ultimately reduces blood glucose (https://ibn.fm/UGKtr).
Most notable from its pilot study was the improved delivery of semaglutide to the bloodstream, which significantly improved blood sugar control. For one, in just 20 minutes after oral administration, the DehydraTECH GLP-1 blood semaglutide level was about 261% higher than that of the Control, a statistic that reflected the technology’s ability to deliver drugs into the bloodstream faster. In addition, 24 hours after the ingestion of a single dose, the DehydraTECH GLP-1 blood semaglutide levels were approximately 44% higher than the Control levels.
The Rybelsus control witnessed a large increase in blood-glucose levels after eating a standardized meal at the 240-minute mark and a standardized snack at the 360-minute mark. But the DehydraTECH processed Rybelsus continued to reduce blood glucose even after eating. In addition, even as long as 24 hours after dose administration, Lexaria’s DehydraTECH GLP-1 showed a 5.01% reduction in blood glucose level relative to baseline, an indicator of greater efficacy in achieving blood glucose reduction, and helping attenuate the postprandial spikes in blood glucose experienced in the control group.
DehydraTECH GLP-1 processed semaglutide also proved better tolerated than the Rybelsus tablets, with the latter resulting in instances of moderate nausea and moderate diarrhea.
Lexaria first announced its intention to explore DehydraTECH’s effectiveness on GLP-1 drugs in September 2023. From the beginning, the goal was to achieve superior pharmacokinetic (“PK”) performance with the technology with reduced side effects and enhanced health benefits. With the just-released final results, Lexaria has achieved these objectives and more, ultimately setting itself up for additional human and animal studies in the 2024 calendar year.
This milestone brings Lexaria closer to tapping into the diabetes treatment market, valued at $92.97 billion in 2023 and projected to reach $118.77 billion by 2028 (https://ibn.fm/lsAji). It also marks an excellent start to the new year 2024, propping the company up for what will be its best year yet. Lexaria is already preparing for other human and animal studies to continue, details of which will be shared in the coming weeks.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About MissionIR
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
For more information, please visit www.MissionIR.com
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer
MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com
MissionIR is powered by IBN
